Dr. Rohit Bharat, Ph.D., International Diagnostics Lead HRR (Prostate Cancer), AstraZeneca
Mr. Ramesh Srinivasan, General Manager – Business Development (Asia), 4baseCare
Mr. Hitesh Goswami, CEO, 4baseCare Dr. Subhankar Basak, Ph.D., India Health Innovation Hub Lead, AstraZeneca
Mr. Kshitij Rishi, COO, 4baseCare
Mumbai, 09 November 2022: India’s leading precision oncology start-up 4baseCare today announced a collaboration with AstraZeneca India, a global science-led biopharmaceutical company for advancing cancer care in India. Under this collaboration, the two organizations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions.
Historically, most of these tests were unavailable locally and were imported burdening the cost of treatment. As a part of the collaboration, AstraZeneca and 4baseCare will work with the oncologist community to support a large number of patients by providing these services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes.
According to a report by ICMR on the ‘Burden of cancers in India’, seven cancers accounted for more than 40% of the total disease burden; lung and breast cancer being the highest. The number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021. Given the advancement of technology in current times, patients have an opportunity to benefit significantly from various new age strategies including ‘Precision Oncology’. It helps provide targeted therapy to patients by identifying which drugs would work best on which patient depending upon the unique biology of a patient’s disease. Genomics-based molecular profiling is the bedrock of targeted therapy and has proved to be a life-saving diagnostics tool as it helps identify the best medical intervention path while treating a patient.
Hitesh Goswami, CEO of 4baseCare points out, “There are 15 lakh new cancer patients diagnosed every year, and more than 60% have advanced-stage cancer that can benefit from targeted therapy. 4baseCare’s vision is to make comprehensive genomic profiling as affordable and accessible as doing an MRI or PET scan is expensive. This technology could be used to guide and personalize treatment for every advanced-stage cancer patient”.
Dr. Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India adds, “AstraZeneca has always been at the forefront of bringing and enhancing access to advanced technology-based solutions for medical and patient benefits. We are committed to pushing the boundaries of science and transforming the lives of patients through the right partnerships. Our current collaboration with 4baseCare is advancing this vision and is aimed at integrating the use of advanced comprehensive genomics as a part of regular clinical practice.
This will take us a step closer to strengthening the oncology ecosystem in the country thereby providing potential opportunities for improving long-term outcomes significantly”.After doing massive research in collaboration with top hospitals and oncologists from India, 4baseCare recently launched another gene panel called TARGT IndieGene panel. TARGT Indiegene, is India’s largest and first population-specific tumor gene panel derived from Whole Exome and Whole Transcriptome data from over 1,500 cancer patients across 28 different cancer types.